|1.||Fasani, Elisa: 2 articles (11/2014 - 01/2008)|
|2.||Albini, Angelo: 2 articles (11/2014 - 01/2008)|
|3.||Attia, Sabry M: 2 articles (06/2009 - 11/2008)|
|4.||Okada, Kyoji: 2 articles (01/2009 - 10/2004)|
|5.||Suzuki, Toshio: 2 articles (01/2009 - 10/2004)|
|6.||Komori, Chiyo: 2 articles (01/2009 - 10/2004)|
|7.||Mozhokina, G N: 2 articles (01/2005 - 01/2000)|
|8.||Sokolova, G B: 2 articles (01/2005 - 01/2000)|
|9.||Elistratova, N A: 2 articles (01/2005 - 01/2000)|
|10.||Kawamura, Yasuhito: 2 articles (06/2002 - 06/2002)|
|1.||Urinary Tract Infections (Urinary Tract Infection)
04/06/1992 - "Once-daily oral lomefloxacin is a well-tolerated and effective treatment of uncomplicated urinary tract infections caused by susceptible pathogens."
09/01/1993 - "[A clinical study of lomefloxacin on the patients with urinary tract infections--focused on lomefloxacin-induced photosensitivity reaction]."
09/28/1996 - "Lomefloxacin was the only antibiotic currently authorized for use in a three-day regimen for the treatment of lower urinary tract infections."
06/01/1996 - "The efficacy and safety of lomefloxacin 400 mg daily in the treatment of complicated urinary tract infections were confirmed in a randomized multicenter study that enrolled 294 patients from 16 centers in Italy. "
09/01/1993 - "Between April and October 1990, photosensitivity reactions were observed in 19 out of 338 patients who were administered lomefloxacin (LFLX) for the treatment of urinary tract infections (UTI) in our hospital. "
12/01/1992 - "Once-daily lomefloxacin is a safe and effective treatment for secondary bacterial skin and skin structure infections caused by susceptible pathogens."
04/06/1992 - "Infection in the elderly: studies with lomefloxacin."
05/01/1989 - "The role of lomefloxacin in the treatment of infections caused by multiresistant organisms remains to be determined in clinical trials."
04/01/1989 - "[Studies of lomefloxacin in biliary tract infections]."
10/01/1988 - "This study suggests that either once-daily or twice-daily dosage of lomefloxacin should be sufficient to treat urinary or systemic infections, respectively, caused by susceptible pathogens."
04/06/1992 - "The results of this study demonstrate that once-daily treatment with 400 mg lomefloxacin is as effective as twice-daily dosing with 400 mg in patients with acute bacterial exacerbations of chronic bronchitis."
12/01/1992 - "In conclusion, once-daily lomefloxacin is a safe and effective treatment for acute exacerbations of chronic bronchitis caused by Gram-negative pathogens."
01/01/1998 - "[Efficacy of lomefloxacin in treatment of patients with chronic bronchitis]."
04/06/1992 - "This study was designed to assess whether a dose response exists for 400 mg lomefloxacin given once daily or twice daily for 10 days in the treatment of acute bacterial exacerbations of chronic bronchitis of gram-negative etiology. "
12/01/2001 - "Lomefloxacin is a difluorinated quinolone with excellent activity against a wide range of pathogens including those responsible for acute exacerbations of chronic bronchitis (AECB). "
06/01/1996 - "Lomefloxacin 0.3% ophthalmic solution demonstrated a high efficacy and good tolerance in the management of acute bacterial conjunctivitis."
06/01/1996 - "Topical lomefloxacin twice daily compared with fucidic acid in acute bacterial conjunctivitis."
10/01/1999 - "Lomefloxacin and ofloxacin were equally effective and safe in the treatment of acute bacterial conjunctivitis."
01/01/1999 - "Topical lomefloxacin 0.3% twice daily versus tobramycin 0.3% in acute bacterial conjunctivitis: A multicenter double-blind phase III study."
01/01/1998 - "191 patients (lomefloxacin 96, chloramphenicol 95) were enrolled in this study with clinically diagnosed acute bacterial conjunctivitis. "
|5.||Respiratory Tract Infections (Respiratory Tract Infection)
04/06/1992 - "This study confirms that lomefloxacin achieves high tissue concentrations in the respiratory tree; this characteristic, together with lomefloxacin's antibacterial spectrum, indicates promise in the treatment of many respiratory infections."
01/01/1993 - "A comparative clinical study of lomefloxacin hydrochloride (LFLX) was performed to confirm the optimal dose of LFLX for treatment of respiratory tract infections. "
01/01/1993 - "[A clinical study on lomefloxacin to find appropriate dose levels in the treatment of respiratory tract infections]."
11/01/1992 - "Steady-state pharmacokinetics and sputum penetration of lomefloxacin in patients with chronic obstructive pulmonary disease and acute respiratory tract infections."
09/01/1992 - "Lomefloxacin has demonstrated comparable efficacy to other therapies in the treatment of lower respiratory-tract infections and urinary-tract infections (UTIs) and for prophylaxis before surgical procedures in the urinary tract. "
|6.||Trimethoprim-Sulfamethoxazole Combination (Co-Trimoxazole)
|1.||Transurethral Resection of Prostate (TURP)
|3.||Oral Surgery (Maxillofacial Surgery)
|4.||Drug Therapy (Chemotherapy)